Intracolonic hydrogen sulfide lowers blood pressure in rats

Nitric Oxide - Biology and Chemistry

Volumn 60, Issue , 2016, Pages 50-58

  Tomasova, Lenka ^a,b,e   Dobrowolski, Leszek ^c   Jurkowska, Halina ^d   Wróbel, Maria ^d   Huc, Tomasz ^a   Ondrias, Karol ^e   Ostaszewski, Ryszard ^f   Ufnal, Marcin ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Faculty of Natural Sciences   (Slovakia)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e INSTITUTE OF CHEMISTRY   (Slovakia)

^f INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

Author keywords

Blood pressure; Gut bacteria; H2S; Hypertension; Microbiota

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLIBENCLAMIDE; HYDROGEN SULFIDE; NEOMYCIN; THIOSULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL HYPERTENSION; HEMODYNAMICS; INTRACOLONIC DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC VEIN; MICROFLORA; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VEIN BLOOD FLOW; WISTAR KYOTO RAT; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; HEART RATE; INTESTINE FLORA; RECTAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, RECTAL; ANIMALS; BLOOD PRESSURE; GASTROINTESTINAL MICROBIOME; GLYBURIDE; HEART RATE; HYDROGEN SULFIDE; MESENTERIC VEINS; RATS; RATS, INBRED SHR; RATS, WISTAR;

EID: 84989170969     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2016.09.007     Document Type: Article

References (59)

1. [1] Liu, Y.H., Lu, M., Hu, L.F., Wong, P.T., Webb, G.D., Bian, J.S., Hydrogen sulfide in the mammalian cardiovascular system. Antioxid. Redox Signal 17 (2012), 141–185.
2. [2] Oosterhuis, N.R., Frenay, A.R.S., Wesseling, S., Snijder, P.M., Slaats, G.G., Yazdani, S., Fernandez, B.O., Feelisch, M., Giles, R.H., Verhaar, M.C., Joles, J.A., Van Goor, H., DL-propargylglycine reduces blood pressure and renal injury but increases kidney weight in angiotensin-II infused rats. Nitric Oxide 49 (2015), 56–66.
3. [3] Roy, A., Khan, A.H., Islam, M.T., Prieto, M.C., Majid, D.S.A., Interdependency of cystathione γ-lyase and cystathione β-synthase in hydrogen sulfide-induced blood pressure regulation in rats. Am. J. Hypertens. 25 (2012), 74–81.
4. + channel-dependent decrease in blood pressure in freely moving rats. Neuroscience 152 (2008), 169–177.
5. [5] Ali, M.Y., Ping, C.Y., Mok, Y.Y.P., Ling, L., Whiteman, M., Bhatia, M., Moore, P.K., Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?. Br. J. Pharmacol. 149 (2006), 625–634.
6. [6] Sikora, M., Drapala, A., Ufnal, M., Exogenous hydrogen sulfide causes different hemodynamic effects in normotensive and hypertensive rats via neurogenic mechanisms. Pharmacol. Rep. 66 (2014), 751–758.
7. 2S-induced nitric oxide release from S-nitrosoglutathione. Physiol. Res. 64 (2014), 479–486.
8. 2S and NaHS in the rat. Am. J. Physiology - Heart Circulatory Physiology 309 (2015), H605–H614.
9. [9] Wallace, J.L., Wang, R., Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat. Rev. Drug Discov. 14 (2015), 329–345.
10. V3 and RyR2 channels. Nitric Oxide 46 (2015), 131–144.
11. ATP channel opener. EMBO J. 20 (2001), 6008–6016.
12. [12] Furne, J., Saeed, A., Levitt, M.D., Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. Am. J. Physiology – Regul. Integr. Comp. Physiology 295 (2008), R1479–R1485.
13. [13] Blachier, F., Davila, A.M., Mimoun, S., Benetti, P.H., Atanasiu, C., Andriamihaja, M., Benamouzig, R., Bouillaud, F., Tomé, D., Luminal sulfide and large intestine mucosa: friend or foe?. Amino Acids 39 (2010), 335–347.
14. [14] Olson, K.R., Hydrogen sulfide: both feet on the gas and none on the brake?. Front. Physiol., 4, 2013, 2.
15. [15] Gaci, N., Borrel, G., Tottey, W., O'Toole, P.W., Brugere, J.F., Archaea and the human gut: new beginning of an old story. World J. Gastroenterol. 20 (2014), 16062–16078.
16. [16] Martin, G.R., McKnight, G.W., Dicay, M.S., Coffin, C.S., Ferraz, J.G.P., Wallace, J.L., Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig. Liver Dis. 42 (2010), 103–109.
17. [17] Ufnal, M., Sikora, M., Szczepanska-Sadowska, E., Interleukin-1 receptor antagonist reduces the magnitude of the pressor response to acute stress. Neurosci. Lett. 448 (2008), 47–51.
18. [18] Shih, V.E., Carney, M.M., Mandell, R., A simple screening test for sulfite oxidase deficiency: detection of urinary thiosulfate by a modification of Sorbo's method. Clin. Chim. Acta 95 (1979), 143–145.
19. [19] Wood, Sulfane Sulfur. Jakoby, W.B., Griffith, O.W., (eds.) Methods in Enzymology, vol. 143, 1987, Academic Press, San Diego, 25–29.
20. [20] Kmecova, J., Klimas, J., Heart rate correction of the QT duration in rats. Eur. J. Pharmacol. 641 (2010), 187–192.
21. [21] Ufnal, M., Zadlo, A., Ostaszewski, R., TMAO: a small molecule of great expectations. Nutrition 31 (2015), 1317–1323.
22. [22] Yang, T., Santisteban, M.M., Rodriguez, V., Li, E., Ahmari, N., Carvajal, J.M., Zadeh, M., Gong, M., Qi, Y., Zubcevic, J., Sahay, B., Pepine, C.J., Raizada, M.K., Mohamadzadeh, M., Gut dysbiosis is linked to hypertension. Hypertension 65 (2015), 1331–1340.
23. [23] Wang, R., Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol. Rev. 92 (2012), 791–896.
24. [24] Barr, L.A., Calvert, J.W., Discoveries of hydrogen sulfide as a novel cardiovascular therapeutic. Circulation J. 78 (2014), 2111–2118.
25. [25] Zoccali, C., Catalano, C., Rastelli, S., Blood pressure control: hydrogen sulfide, a new gasotransmitter, takes stage. Nephrol. Dial. Transplant. 24 (2009), 1394–1396.
26. [26] Ufnal, M., Sikora, M., The role of brain gaseous transmitters in the regulation of the circulatory system. Curr. Pharm. Biotechnol. 12 (2011), 1322–1333.
27. [27] Pimentel, M., Mathur, R., Chang, C., Gas and the microbiome. Curr. Gastroenterol. Rep., 15, 2013, 356.
28. [28] Yan, H., Du, J., Tang, C., The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem. Biophysical Res. Commun. 313 (2004), 22–27.
29. [29] Shi, Y.X., Chen, Y., Zhu, Y.Z., Huang, G.Y., Moore, P.K., Huang, S.H., Yao, T., Zhu, Y.C., Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am. J. Physiology – Heart Circulatory Physiology 293 (2007), H2093–H2100.
30. [30] Ali, M.Y., Ping, C.Y., Mok, Y.Y., Ling, L., Whiteman, M., Bhatia, M., Moore, P.K., Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?. Br. J. Pharmacol. 149 (2006), 625–634.
31. [31] Zhao, X., Zhang, L.K., Zhang, C.Y., Zeng, X.J., Yan, H., Jin, H.F., Tang, C.S., Du, J.B., Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens. Res. 31 (2008), 1619–1630.
32. [32] Li, L., Whiteman, M., Guan, Y.Y., Neo, K.L., Cheng, Y., Lee, S.W., Zhao, Y., Baskar, R., Tan, C.H., Moore, P.K., Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 117 (2008), 2351–2360.
33. [33] Stubbert, D., Prysyazhna, O., Rudyk, O., Scotcher, J., Burgoyne, J.R., Eaton, P., Protein kinase G Iα oxidation paradoxically underlies blood pressure lowering by the reductant hydrogen sulfde. Hypertension 64 (2014), 1344–1351.
34. [34] Cortese-Krott, M.M., Kuhnle, G.G., Dyson, A., Fernandez, B.O., Grman, M., DuMond, J.F., Barrow, M.P., McLeod, G., Nakagawa, H., Ondrias, K., Nagy, P., King, S.B., Saavedra, J.E., Keefer, L.K., Singer, M., Kelm, M., Butler, A.R., Feelisch, M., Key bioactive reaction products of the NO/H2S interaction are S/N-hybrid species, polysulfides, and nitroxyl. Proc. Natl. Acad. Sci. 112 (2015), E4651–E4660.
35. [35] Ogasawara, Y., Isoda, S., Tanabe, S., Tissue and subcellular distribution of bound and acid-labile sulfur, and the enzymic capacity for sulfide production in the rat. Biol. Pharm. Bull. 17 (1994), 1535–1542.
36. [36] Ishigami, M., Hiraki, K., Umemura, K., Ogasawara, Y., Ishii, K., Kimura, H., A source of hydrogen sulfide and a mechanism of its release in the brain. Antioxid. Redox Signal 11 (2009), 205–214.
37. [37] Berenyiova, A., Grman, M., Mijuskovic, A., Stasko, A., Misak, A., Nagy, P., Ondriasova, E., Cacanyiova, S., Brezova, V., Feelisch, M., The reaction products of sulfide and S-nitrosoglutathione are potent vasorelaxants. Nitric Oxide 46 (2015), 123–130.
38. [38] Ondrias, K., Stasko, A., Cacanyiova, S., Sulova, Z., Krizanova, O., Kristek, F., Malekova, L., Knezl, V., Breier, A., H2S and HS− donor NaHS releases nitric oxide from nitrosothiols, metal nitrosyl complex, brain homogenate and murine L1210 leukaemia cells. Pflügers Archiv-European J. Physiology 457 (2008), 271–279.
39. ATP channels in vascular smooth muscle. Clin. Exp. Pharmacol. Physiol. 29 (2002), 312–316.
40. [40] Cheng, Y., Ndisang, J.F., Tang, G., Cao, K., Wang, R., Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am. J. Physiol. Heart Circ. Physiol. 287 (2004), H2316–H2323.
41. [41] Kiss, L., Deitch, E.A., Szabó, C., Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. Life Sci. 83 (2008), 589–594.
42. [42] Webb, G.D., Lay, H.L., Oh, V.M.S., Soh, B.Y., Yoke, P.C., Ali, M.Y., El Oakley, R., Chuen, N.L., Poo, S.W., Caleb, M.G., Salto-Tellez, M., Bhatia, M., Chan, E.S.Y., Taylor, E.A., Moore, P.K., Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. J. Pharmacol. Exp. Ther. 324 (2008), 876–882.
43. [43] Al-Magableh, M.R., Hart, J.L., Mechanism of vasorelaxation and role of endogenous hydrogen sulfide production in mouse aorta. Naunyn-Schmiedeberg's Archives Pharmacol. 383 (2011), 403–413.
44. ATP channel blockers. Amino Acids 48 (2016), 1581–1590.
45. [45] Kawada, T., Sata, Y., Shimizu, S., Turner, M.J., Fukumitsu, M., Sugimachi, M., Effects of tempol on baroreflex neural arc versus peripheral arc in normotensive and spontaneously hypertensive rats. Am. J. Physiology – Regul. Integr. Comp. Physiology 308 (2015), R957–R964.
46. [46] Xie, H.H., Shen, F.M., Zhang, X.F., Jiang, Y.Y., Su, D.F., Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs. Eur. J. Pharmacol. 543 (2006), 77–82.
47. + channels in endocardial myocytes from left ventricular hypertrophy. Am. J. Physiology - Heart Circulatory Physiology 293 (2007), H3643–H3649.
48. [48] Mishanina, T.V., Libiad, M., Banerjee, R., Biogenesis of reactive sulfur species for signaling by hydrogen sulfide oxidation pathways. Nat. Chem. Biol. 11 (2015), 457–464.
49. [49] Toohey, J.I., Cooper, A.J., Thiosulfoxide (sulfane) sulfur: new chemistry and new regulatory roles in biology. Molecules 19 (2014), 12789–12813.
50. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322 (2008), 587–590.
51. [51] Meng, G., Ma, Y., Xie, L., Ferro, A., Ji, Y., Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br. J. Pharmacol. 172 (2014), 5501–5511.
52. 2S bioavailability in endothelial dysfunction. Trends Pharmacol. Sci. 36 (2015), 568–578.
53. [53] Jose, P.A., Raj, D., Gut microbiota in hypertension. Curr. Opin. Nephrol. Hypertens. 24 (2015), 403–409.
54. [54] Mell, B., Jala, V.R., Mathew, A.V., Byun, J., Waghulde, H., Zhang, Y., Haribabu, B., Vijay-Kumar, M., Pennathur, S., Joe, B., Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol. Genomics 47 (2015), 187–197.
55. [55] Shen, X., Carlstrom, M., Borniquel, S., Jadert, C., Kevil, C.G., Lundberg, J.O., Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic. Biol. Med. 60 (2013), 195–200.
56. [56] Huc, T., Pham, K., Skrzypecki, J., Ufnal, M., Significance of gut-blood barrier in health and disease. Eur. J. Biol. Res. 6 (2016), 193–200.
57. [57] Hanada, E., Ohtani, H., Kotaki, H., Sawada, Y., Sato, H., Iga, T., Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. J. Pharm. Sci. 88 (1999), 234–240.
58. [58] Wood, A.J., Roden, D.M., Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350 (2004), 1013–1022.
59. [59] Skrzypecki, J., Ufnal, M., Drug resistant hypertension – no simple way out. Kidney Blood Press Res. 40 (2015), 66–76.